Lumida
/PHAT
⌘K
Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc

PHAT
$8.36USD-0.12%-0.01 today

MARKET CAP

676.3M

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $9

52W RANGE

$8
$18

AI Summary

Stalk
Sell NowMedium

Intermediate bearish pressure remains dominant for PHAT as price trades below declining EMAs with repeated rejection at moving average resistance, favoring selling into failed relief rallies around the 9/21/50 EMA confluence for tactical downside participation while acknowledging the longer-term uptrend.

  • Q4 2025 revenue of $57.6M rose 217% YoY, meeting guidance
  • Q2 2026 delivered positive operating profit ex-stock comp for first time
  • Full-year 2025 revenue of $175.1M masks ongoing profitability challenges
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$682,000$55.3M$175.1M
YoY %+8001.5%+216.9%
P / Sales689.6x9.3x6.9x
EV / Sales843.9x15.3x10.1x
Gross Profit, Adj.$515,000$47.3M$152.5M
YoY %+9080.4%+222.6%
Margin %75.5%85.6%87.1%
EV / Gross Profit1117.5x17.9x11.7x
EBITDA, Adj.$-166.7M$-276.7M$-159.4M
YoY %+3.0%-65.9%+42.4%
Margin %-24448.2%-500.7%-91.0%
EV / EBITDA-3.5x-3.1x-11.2x
EBIT$-167.3M$-277.5M$-160.0M
YoY %+3.0%-65.8%+42.3%
Margin %-24532.6%-502.2%-91.4%
EV / EBIT-3.4x-3.1x-11.1x
Net Income$-201.6M$-334.3M$-221.2M
YoY %-2.0%-65.8%+33.8%
Net Margin-29558.9%-605.1%-126.3%
EPS (GAAP)-$3.93-$5.29-$3.03
YoY %+22.2%-34.6%+42.7%